DiaMedica Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

DiaMedica Therapeutics

14/03/2025 20:28

DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to show no change in quarterly revenue when it reports  results on March 17 for the period ending December 31 2024

​LSEG's mean analyst estimate for DiaMedica Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $7.50​, above​ its last closing price of $5.67. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.15
-0.15
-0.15
Met
3.2
Jun. 30 2024
-0.15
-0.16
-0.13
Beat
17
Mar. 31 2024
-0.16
-0.16
-0.14
Beat
10.6​
Dec. 31 2023
-0.14
-0.14
Met
0
​​Sep. 30 2023
-0.14
-0.13
-0.12
Beat
5.3
Jun. 30 2023
-0.19
-0.18
-0.16
Beat
9.4​
Mar. 31 2023
-0.15
-0.16
-0.20
Missed
-25
Dec. 31 2022
-0.14
-0.14
Met
0

This summary was machine generated March 14 at 20:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)